Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
RESEARCH TOOLSreports
NEU Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$8.61 - AU$24.00
Previous CloseN/A
Volume294.48K
Average Volume (3M)878.86K
Market Cap
$1.42B
Enterprise ValueAU$2.57B
Total Cash (Recent Filing)AU$36.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)9.9
Beta1.89
Next Earnings
Aug 26, 2025EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding127,993,380
10 Day Avg. Volume1,352,601
30 Day Avg. Volume878,859
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)N/A
Price to Sales (P/S)123.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$26.60Price Target Upside161.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Neuren Pharmaceuticals Limited News
PremiumCompany Announcements
Neuren Pharmaceuticals Continues Daily Securities Buy-Back
PremiumCompany Announcements
Neuren Pharmaceuticals Director Increases Shareholding
PremiumCompany Announcements
Neuren Pharmaceuticals Advances Phase 3 Trial for Phelan-McDermid Syndrome
PremiumCompany Announcements
Neuren Pharmaceuticals Updates on Share Buy-Back Program
PremiumCompany Announcements
Neuren Pharmaceuticals Updates on Share Buy-Back Progress
PremiumCompany Announcements
Neuren Pharmaceuticals Announces Cessation of Securities via Buy-Back
PremiumCompany Announcements
Neuren Pharmaceuticals Updates on Buy-Back Program
PremiumCompany Announcements
Neuren Pharmaceuticals Releases 2024 Corporate Governance Statement---
Options Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
2.68%
Mutual Funds
<0.01% Other Institutional Investors
94.28% Public Companies and
Individual Investors
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$8.61 and its highest was AU$24.00 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Neuren Pharmaceuticals Limited’s market cap is $1.42B.
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Aug 26, 2025 which is in 131 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Feb 27, 2025. The company reported AU$1.022 earnings per share for the quarter, missing the consensus estimate of AU$1.036 by -AU$0.014.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is 0.07.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 127,993,380 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$1.022 in its last earnings report, missing expectations of AU$1.036. Following the earnings report the stock price went down -6.831%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
---
Neuren Pharmaceuticals Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$26.60 (161.59% Upside)
AU$26.60 (161.59% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 96%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $97.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.49%
12-Months-Change
Fundamentals
Return on Equity
51.39%
Trailing 12-Months
Asset Growth
49.92%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
---
NEU Company Deck
---
NEU Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Neuren's strong financial performance, significant cash growth, and successful collaboration with Acadia. Positive trial results for NNZ-2591 and an expanded global reach were significant achievements. However, challenges such as tax liabilities, exchange rate impacts, and share price volatility were noted. Overall, the positive aspects and strategic advancements overshadow the lowlights.Read More>---
NEU Stock 12 Month Forecast
Average Price Target
AU$26.60
▲(161.59% Upside)
Technical Analysis
Acrux Limited
―
Paradigm Biopharmaceuticals Ltd.
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Race Oncology Ltd.
―
Best Analysts Covering NEU
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+7.66%
reiterated a buy rating 2 months ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +7.66% per trade.
---